ev3, an endovascular device company, has reportedly reached an agreement with the plaintiffs to settle the claims asserted in the stockholder class action lawsuits related to Covidien's proposed acquisition of ev3.

While endovascular approaches to treat thoracic aortic aneurysms may be promising for patients, there is still room for complications including endoleak and neurological problems, according to study results published online June 14 in Circulation.

Spectranetics is initiating a new clinical trial to evaluate treatment of in-stent restenosis in arteries above the knee. There is no device currently approved by the FDA to treat ISR.

Annually, 50,000 new stroke cases occur in Canada. And, these new cases equate to almost $2.5 billion each year in healthcare costs for just the first six months after a stroke, according to a study presented June 8 at the Canadian Stroke Congress (CSC) in Quebec City.

A clinical trial studying the safety and effectiveness of Cardiovascular Systems Diamondback 360 system to treat peripheral arterial disease above the knee has competed its patient enrollment.

Cardiovascular Systems has instituted a $25 million credit facility with Silicon Valley Bank, and $4 million in convertible debt with Partners for Growth for the consolidation of outstanding debt and the production of working capital.

Endologix has begun enrolling patients into its PEVAR clinical trial that will investigate the use of a bilateral percutaneous approach for endovascular abdominal aortic aneurism repair.

The next breakthrough drug or device in cardiovascular medicine might have its beginnings in Cleveland. A start-up company incubator, which is focused on helping companies develop cardiovascular drug therapies, devices and services, is projected to open in Mayin close proximity to its leading partner, the Cleveland Clinic.